Participants will enroll in a 14-week study (2 weeks of baseline, 8 weeks of treatment, and 4 weeks of follow-up) investigating the impact that Alkontrol-herbal (Isoflavone; Kudzu) has on alcohol intake in a population seeking treatment for an alcohol use disorder.
Over the past 15 years, the Behavioral Psychopharmacology Research Lab at McLean Hospital has extensively studied kudzu extract and demonstrated its safety and efficacy in healthy control subjects as well as in heavy binge drinkers. The relative success of our recent outpatient trial of kudzu extract demonstrated a modest decrease in drinking, reduction in the number of heavy drinking days, and significant increase in the number of days abstinent. This suggests that Alkontrol-herbal, kudzu extract, may be a useful adjunct in treating alcohol use disorders. Participants will enroll in a 14-week study (2 weeks of baseline, 8 weeks of treatment, and 4 weeks of follow-up) investigating the impact that Alkontrol-herbal has on alcohol intake in a population (age 21-60 years) seeking treatment for an alcohol use disorder. Participants will take 500 mg of a crude kudzu extract (NPI-031, Alkontrol-herbal; Natural Pharmacia International, Burlington, MA) t.i.d.; matched sugar beet placebo capsules will serve as placebo. Subjects will come to the lab three times a week to provide urine samples that can be tested for medication compliance through a biochemical marker, acetazolamide, included in the medication capsules. Participants will record their alcohol intake through daily diaries and a wrist actigraphy device, which will also monitor their sleep/wake activity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
28
Capsules containing 500 mg of a crude kudzu extract (NPI-031, Alkontrol-herbal; Natural Pharmacia International, Burlington, MA) will be used, containing 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
Matched sugar beet placebo capsules will serve as placebo.
McLean Hospital
Belmont, Massachusetts, United States
percent days abstinent
percent days abstinent from alcohol
Time frame: change from baseline to post 8 weeks of treatment
drinks/day
number of alcoholic drinks/day reported
Time frame: change from baseline to post 8 weeks of treatment
number (or percent) of heavy drinking days
number (or percent) of heavy drinking days
Time frame: change from baseline to post 8 weeks of treatment
percent days abstinent
percent days abstinent from alcohol
Time frame: change from baseline to 4 weeks follow-up post-treatment
drinks/day
number of alcoholic drinks/day reported
Time frame: change from baseline to 4 weeks follow-up post-treatment
number (or percent) of heavy drinking days
number (or percent) of heavy drinking days
Time frame: change from baseline to 4 weeks follow-up post-treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.